Seth FlaumPARTNER

TechnologyTransactions
New Yorksﬂaum@wsgr.com

212-453-2870

FOCUS AREAS
BiotechCorporate
Emerging Companies
Life Sciences
Medical Devices
Technology Transactions

HIGHLIGHTSLife Sciences Expertise

Seth represents pharmaceutical, biotechnology, medical device, diagnostic, and other technologybased companies in a wide range of strategic transactions and corporate matters.

Extensive In-House Transactional Experience

Seth has more than 16 years of experience serving as in-house counsel at a global pharmaceuticalcompany, where he advised on an array of strategic transactions and managed a team of lawyers
and business professionals responsible for implementing intellectual property and businessdevelopment transactions.

EXPERIENCE
Seth Flaum is a partner in the New York oﬃce of Wilson Sonsini Goodrich & Rosati, where he is amember of the technology transactions practice. With more than 25 years of broad transactional
experience, he represents life sciences companies in a wide range of strategic transactions andcorporate matters.
Prior to joining the ﬁrm, Seth was the executive associate general counsel for Daiichi Sankyo, Inc., aglobal pharmaceutical company based in Japan, where he trained and managed a team of lawyersand business professionals responsible for implementing the company's global businessdevelopment transactions. In this role, Seth counseled on strategic transactions, structuring,negotiating, and drafting strategic collaboration agreements, licensing agreements, research anddevelopment agreements, co-promotion agreements, commercialization agreements, optionagreements, material transfer agreements, clinical trial agreements, CRO agreements, distributionagreements, manufacturing and supply agreements, and other transactions. He also has experience
with public and private M&A transactions, and has advised on antitrust issues and ﬁlings, FINRA
inquiries, SEC ﬁlings, and corporate governance matters.
Before joining Daiichi Sankyo, Seth was a senior associate at Ullman, Shapiro & Ullman, LLP in New
York. Previously, he was general counsel at H&H Bagels, corporate counsel at Thompson Medical
Company and Slim Fast Foods Company, and an associate at D'Erasmo, Shure & Perez in Rockville,Maryland.

CREDENTIALS
Education

J.D., Loyola Law School, 1994
B.S., Finance, New York University Leonard N. Stern School of Business, 1991

Copyright © 2023 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.Admissions

State Bar of New Jersey
State Bar of New YorkMATTERS

Illustrative Representations
Pharmaceutical and Diagnostic Collaboration Agreements
Daiichi Sankyo in its global development and commercialization collaboration with AstraZeneca
for TROP2-directed antibody drug conjugate (ADC) DS-1062*
Daiichi Sankyo in its strategic coalition with CRO Syneos Health to develop an ADC oncology
pipeline*
Daiichi Sankyo in its global development and commercialization collaboration with AstraZeneca
for HER2-directed ADC DS-8201 (Enhertu®)*
Daiichi Sankyo in its clinical trial combination agreement with Merck for DS-1062 and Keytruda®
and with Bristol-Myers Squibb for DS-8201 (Enhertu®) and Opdivo®*
Daiichi Sankyo in its strategic collaboration in Japan with Kite Pharma Inc. for a cell therapyproduct ( Yescarta®)*Daiichi Sankyo in multiple collaboration agreements with Portola Pharmaceuticals and withPerosphere (acquired by AMAG) for factor Xa reversal agents*
Daiichi Sankyo in its strategic collaboration and co-promotion agreement with AstraZeneca for asmall molecule product for opioid induced constipation (Movantik®)*
Daiichi Sankyo in its strategic collaboration and option agreement with Amplimmune (acquiredby AstraZeneca) for an immune modulation therapy*
Daiichi Sankyo in its exclusive licensing agreement in Japan with Coherus Biosciences forselect biosimilars*
Daiichi Sankyo in multiple exclusive worldwide licensing agreements with ArQule (acquired byMerck) for small molecule oncology products*
Daiichi Sankyo in its authorized generic distribution agreements with Ranbaxy Pharmaceuticals
and Sun Pharmaceuticals*
Daiichi Sankyo in its global collaboration with Invivoscribe and other prominent diagnostic
companies for companion diagnostics*
Daiichi Sankyo in its research collaboration with DarwinHealth*Daiichi Sankyo in its multiple alliance agreements with Sanford-Burnham Medical ResearchInstitute*Venture Science Laboratories in its drug discovery research collaboration with University ofCalifornia San Francisco (UCSF) to develop novel therapeutics and molecular diagnostics for
multiple neurodegenerative diseases*
Mergers and Acquisitions and Divestitures
Plexxikon in its sale of a portfolio of small molecule oncology therapeutics and other assets
to Opna Bio*
Daiichi Sankyo in the divestiture of its pharmaceutical packaging plant and laboratory to Sharp
Packaging Services, a division of UDG Healthcare*
Daiichi Sankyo in its acquisition of Ambit Biosciences*
Daiichi Sankyo in its sale of Ranbaxy Laboratories to Sun Pharmaceuticals *Daiichi Sankyo in its acquisition of Plexxikon** Denotes experience prior to joining Wilson Sonsini in 2022.

Copyright © 2023 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.